Cannabis Use Disorder
A clinical diagnosis defined by impaired control, withdrawal, and harm—treatable with behavioral therapy and emerging medications.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
Cannabis use disorder is real and treatable, but many people underestimate the risk—especially with daily, high-potency use. About 9% of all users and 30% of daily users develop it. Behavioral therapies like CBT plus motivational enhancement work better than trying to quit alone, but abstinence rates are modest (~15–40% at 6–12 months). No FDA medication exists yet, though several show promise. It's not a moral failing; it's a clinical condition.
Not medical advice
This article is informational only and does not replace clinical evaluation. If you are struggling to cut down or stop, experiencing severe withdrawal, mental health symptoms, or thoughts of self-harm, contact a healthcare provider immediately. In the US:
- 988 Suicide & Crisis Lifeline: Call or text 988
- SAMHSA National Helpline: 1-800-662-4357 (free, confidential, 24/7)
- Crisis Text Line: Text HOME to 741741
Plain-language summary
Cannabis use disorder (CUD) is a clinical diagnosis in the DSM-5 describing a pattern of cannabis use that causes significant impairment or distress Strong evidence[1]. It is defined by 11 diagnostic criteria: tolerance; withdrawal; using more than intended; failed attempts to cut down; cravings; neglect of other activities; continued use despite interference with relationships; engagement in hazardous use; continued use despite physical or psychological problems; spending significant time obtaining, using, or recovering from cannabis; and needing larger amounts to achieve the same effect Strong evidence[1].
Meeting 2–3 criteria indicates mild CUD; 4–5 moderate; 6 or more severe Strong evidence[1]. About 9–10% of people who ever use cannabis develop CUD Strong evidence[2]. The rate climbs to roughly 30% among daily users, and is significantly higher in those who start in adolescence Strong evidence[3].
CUD is treatable with behavioral therapy and emerging medications. Cannabis withdrawal is clinically recognized and real. Symptoms include irritability, sleep disruption, decreased appetite, anxiety, and restlessness. While not medically dangerous like alcohol or benzodiazepine withdrawal, it reliably drives relapse Strong evidence[11].
What probably works: stronger evidence
Behavioral therapies, especially combined approaches
A 2016 Cochrane systematic review of 23 randomized controlled trials concluded that cognitive behavioral therapy (CBT), motivational enhancement therapy (MET), and contingency management (CM) reduce cannabis use frequency and severity Strong evidence[4]. The largest effects occur when CBT and MET are combined and delivered for at least four sessions Strong evidence[4].
CBT + MET (combined): This is the best-supported treatment package. Typical effect sizes are modest (Cohen's d ~0.3–0.5) but consistent across trials. The combination addresses both skill-building (CBT) and ambivalence about change (MET).
Contingency management: Providing financial incentives (vouchers or prizes) for cannabis-negative urine screens reliably reduces use during the active intervention period Strong evidence[4]. Effects substantially diminish after incentives stop, but can support critical early abstinence windows.
Brief interventions in primary care: Structured counseling in non-treatment-seeking settings reduces cannabis use, though effects are smaller than intensive therapy Weak / limited[5].
Important caveat: None of these are cure-alls. Abstinence rates at 6–12 months in rigorous trials vary across studies, and relapse is common. Among treatment-seeking individuals in controlled trials, behavioral therapy does produce greater reductions in use than do unsupported cessation attempts Strong evidence[4], but achieving and maintaining abstinence remains challenging for many.
What might work: weak or emerging evidence
Pharmacotherapy
No medication is FDA-approved for CUD. Several compounds have been tested with mixed or modest results:
N-acetylcysteine (NAC): A 2012 randomized trial in adolescents showed reduction in cannabis use Weak / limited[6]. A larger multisite trial in 2017 across adolescents and adults did not replicate this finding Disputed[7]. Currently considered promising but unproven.
Gabapentin: One small randomized trial demonstrated reduced use and withdrawal symptoms Weak / limited[8]. No large replications exist.
Cannabinoid agonist substitution (dronabinol, nabilone, nabiximols): These medications reliably reduce withdrawal discomfort Weak / limited[9]. Effects on abstinence itself are smaller and inconsistent. Nabiximols (Sativex, a THC:CBD extract) shows the strongest signal but is not available in the United States Weak / limited[9].
Cannabidiol (CBD): A 2020 Phase 2a randomized trial found 400 mg and 800 mg daily CBD reduced cannabis use versus placebo over 4 weeks Weak / limited[10]. This is a single trial of short duration; replication is pending.
Other agents: Topiramate, bupropion, SSRIs, atomoxetine, and naltrexone have been studied; results are generally disappointing Weak / limited[9].
Digital and app-based CBT: Emerging literature suggests modest effectiveness and strong convenience appeal Weak / limited.
Mindfulness-based relapse prevention: Mechanistically plausible but limited cannabis-specific outcome data Weak / limited.
What doesn't work or lacks evidence
Strain-switching or low-myrcene strategies: Marketing folklore suggests switching to a "sativa" or choosing strains low in the terpene myrcene will reduce dependence. Strain name and terpene profile do not reliably predict psychological or dependence-related effects, and there is no controlled evidence this approach helps CUD No data.
CBD-dominant flower for CUD: While theoretically appealing (CBD may counteract some THC effects), almost no controlled trial data support its use for this purpose. Users often add THC-dominant product back Weak / limited.
12-step programs (Marijuana Anonymous) as standalone treatment: These offer valuable peer support for some participants. Controlled outcome data specific to cannabis are very limited Weak / limited.
Acupuncture, homeopathy, detox teas, or ibogaine for cannabis: No credible evidence supports these approaches No data.
What we don't know
- High-potency concentrates and CUD risk: Population-level data link concentrates (>70% THC) to worse mental health outcomes in some studies, but individual-level causal evidence is limited Weak / limited[12]. We do not know whether concentrates meaningfully increase CUD incidence in any given person.
- CBD efficacy: Will the Freeman 2020 positive trial replicate in larger, longer studies? Currently uncertain.
- Optimal cannabinoid taper: If someone uses a THC or CBD:THC product to substitute for higher-potency cannabis (analogous to nicotine replacement for smoking), what dose schedule and duration are most effective? Unknown.
- Pre-morbid risk prediction: No reliable biomarker or clinical tool identifies who will develop CUD before heavy use begins. Genetic, psychiatric, and developmental factors all matter, but predictive precision remains poor.
- Psychedelic-assisted therapy: Psilocybin and ibogaine show emerging promise for some substance use disorders, but cannabis-specific outcome data are entirely anecdotal Anecdote.
Comparison with other substance use disorders
CUD treatment infrastructure lags behind alcohol, opioid, and tobacco use disorder treatment, which all have FDA-approved pharmacological options:
| Substance | FDA-approved medications | Behavioral evidence | Withdrawal safety |
|---|---|---|---|
| Opioid | Buprenorphine, methadone, naltrexone | Strong | Severe but not life-threatening |
| Alcohol | Acamprosate, naltrexone, disulfiram | Strong | Can be life-threatening |
| Tobacco | Varenicline, nicotine replacement, bupropion | Strong | Moderate; not medically dangerous |
| Cannabis | None | Moderate | Mild–moderate; not medically dangerous |
The absence of an approved cannabis medication is a genuine clinical gap. Cannabis withdrawal—while not medically dangerous—causes sufficient discomfort and dysphoria to drive relapse in many people, and behavioral therapy alone does not always suffice. The disorder is treatable and outcomes improve with structured care, but progress on pharmacotherapy remains slow.
Risks and clinical importance
CUD is associated with increased risk of several adverse outcomes:
Psychotic disorder risk: Heavy, chronic cannabis use—especially with high-potency products and adolescent-onset use—is associated with worse outcomes in people with pre-existing psychotic disorders and with increased risk of incident psychosis in vulnerable individuals Strong evidence[13].
Cannabinoid hyperemesis syndrome: Chronic heavy users may develop intractable nausea, vomiting, and abdominal pain relieved only by hot baths or cessation Strong evidence.
Cognitive effects: Sustained heavy cannabis use in adolescents and young adults is linked to deficits in attention, memory, and executive function Strong evidence[14]. Many—but not all—improvements occur with sustained abstinence, and the degree and timing of recovery vary Strong evidence[14].
Cardiovascular events: Limited evidence suggests increased risk of myocardial infarction or stroke in older or already-at-risk users Weak / limited.
Social and occupational impairment: CUD commonly disrupts work, school, driving, and relationships.
Bottom line: Most cannabis users never develop CUD. However, a clinically significant minority do—especially those using daily or high-potency products, starting in adolescence, or with co-occurring mental health conditions. If cannabis use is causing problems and you cannot stop on your own, evidence-based interventions work better than unsupported attempts, and treatment is worth pursuing.
Sources
- Book American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). Arlington, VA: American Psychiatric Publishing.
- Peer-reviewed Hasin, D. S., Saha, T. D., Kerridge, B. T., et al. (2015). Prevalence of Marijuana Use Disorders in the United States Between 2001–2002 and 2012–2013. JAMA Psychiatry, 72(12), 1235–1242.
- Peer-reviewed Hall, W., & Degenhardt, L. (2009). Adverse health effects of non-medical cannabis use. The Lancet, 374(9698), 1383–1391.
- Peer-reviewed Gates, P. J., Sabioni, P., Copeland, J., Le Foll, B., & Gowing, L. (2016). Psychosocial interventions for cannabis use disorder: A systematic review of randomized controlled trials. Cochrane Database of Systematic Reviews, (5), CD005336.
- Peer-reviewed Imtiaz, S., Roerecke, M., Kurdyak, P., et al. (2020). Brief interventions for cannabis use in healthcare settings: A systematic review and meta-analyses of randomized trials. Journal of Addiction Medicine, 14(1), 78–88.
- Peer-reviewed Gray, K. M., Carpenter, M. J., Baker, N. L., et al. (2012). A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. American Journal of Psychiatry, 169(8), 805–812.
- Peer-reviewed Gray, K. M., Sonne, S. C., McClure, E. A., et al. (2017). A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug and Alcohol Dependence, 177, 249–257.
- Peer-reviewed Mason, B. J., Crean, R., Goodell, V., et al. (2012). A proof-of-concept randomized controlled study of gabapentin: Effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology, 37(7), 1689–1698.
- Peer-reviewed Brezing, C. A., & Levin, F. R. (2018). The current state of pharmacological treatments for cannabis use disorder and withdrawal. Neuropsychopharmacology, 43(1), 173–194.
- Peer-reviewed Freeman, T. P., Hindocha, C., Baio, G., et al. (2020). Cannabidiol for the treatment of cannabis use disorder: A phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. The Lancet Psychiatry, 7(10), 865–874.
- Peer-reviewed Bonnet, U., & Preuss, U. W. (2017). The cannabis withdrawal syndrome: Current insights. Substance Abuse and Rehabilitation, 8, 9–37.
- Peer-reviewed Petrilli, K., Ofori, S., Hines, L., et al. (2022). Association of cannabis potency with mental ill health and addiction: A systematic review. The Lancet Psychiatry, 9(9), 736–750.
- Peer-reviewed Di Forti, M., Quattrone, D., Freeman, T. P., et al. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI). The Lancet Psychiatry, 6(5), 427–436.
- Peer-reviewed Scott, J. C., Slomiak, S. T., Jones, J. D., et al. (2018). Association of cannabis with cognitive functioning in adolescents and young adults: A systematic review and meta-analysis. JAMA Psychiatry, 75(6), 585–595.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Bipolar Disorder — Why cannabis use worsens bipolar outcomes despite subjective relief, and what the research...
- Cannabis and Generalized Anxiety Disorder — Weak evidence for acute CBD effects; no proof of long-term benefit; high THC worsens anxie...
- Cannabis and Panic Disorder — Cannabis can trigger panic attacks; evidence for treatment is absent. Standard therapies w...
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- THC Dose and Anxiety — Low doses may reduce acute anxiety; higher doses increase it. Evidence is limited, risks a...